ANTICOAGULANT CITRATE DEXTROSE A ACD-A National Drug Code Directory

Similar documents
POTASSIUM CITRATE CITRIC ACID CRYSTALS National Drug Code Directory

PHENYTOIN SODIUM National Drug Code Directory

DIANEAL LOW CALCIUM WITH DEXTROSE National Drug Code Directory

SODIUM BICARBONATE National Drug Code Directory

DEXAMETHASONE SODIUM PHOSPHATE National Drug Code Directory

MYCAMINE National Drug Code Directory

DIVALPROEX SODIUM National Drug Code Directory

HAVRIX National Drug Code Directory

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG National Drug Code Directory

National Drug Code Directory

SHEER COVER MINERAL FOUNDATION National Drug Code Directory

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE National Drug Code Directory

National Drug Code Directory

SUBSYS National Drug Code Directory

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE National Drug Code Directory

PRIMAXIN National Drug Code Directory

FLUZONE QUADRIVALENT National Drug Code Directory

KETAMINE HYDROCHLORIDE National Drug Code Directory

MORPHINE SULFATE National Drug Code Directory

FLUZONE INTRADERMAL QUADRIVALENT National Drug Code Directory

National Drug Code Directory

CITRANATAL DHA National Drug Code Directory

PEDIATRIC INFUVITE MULTIPLE VITAMINS FOR INFUSION National Drug Code Directory

FLUCELVAX QUADRIVALENT (PREFILLED SYRINGE) National Drug Code Directory

National Drug Code Directory

DAPTACEL National Drug Code Directory

O-CAL FA MULTIVITAMIN National Drug Code Directory

FOLET DHA National Drug Code Directory

THYRO T3 RESCUE National Drug Code Directory

ADRENAL SUPPORT National Drug Code Directory

HERPES SIMPLEX PLUS National Drug Code Directory

LYMPH/SPLEEN COMBO National Drug Code Directory

CLEANSE REMEDY WATER National Drug Code Directory

TRANQUIL REMEDY NO. 11 National Drug Code Directory

CALM REMEDY WATER National Drug Code Directory

BUG BITES - ITCH STOPPER National Drug Code Directory

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

ANDA Labeling Question Based Review September 11, 2013 GPhA/FDA ANDA Labeling Workshop/USP User Forum

Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044

Over-the-Counter Pediatric Liquid Drug Products Containing Acetaminophen

Physician Injectable Drug List (PIDL) Department for Medicaid Services, HP, and Magellan Rx Management June 1, 2010

ORANGE BOOK ORANGE BOOK

Guidance for Industry

NDA NDA APPROVAL

USP Perspective on Atypical Actives November 29, 2017

Calcium Folinate Solution for Injection

Naloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program

ANDA Arthur P. Bedrosian, President Armenpharm, Ltd. 49 South Ridge Road P.O. Box D1400 Pomona, NY December 3, 2015

CENTER FOR DRUG EVALUATION AND RESEARCH. APPLICATION NUMBER: Orig1s000 APPROVAL LETTER

Inspections, Compliance, Enforcement, and Criminal Investigations

DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f

Harmonization effort for OTC monograph in Taiwan. Ms. Hsueh-Yung (Mary) Tai Deputy Director, Division of Medical Product, Taiwan FDA

Three-Month Extension of Certain Tobacco Product Compliance Deadlines Related to the

FEB 28 A 9 :09

Gluten in Drug Products and Associated Labeling Recommendations Guidance for Industry

BAYER ADVANCED ASPIRIN REGULAR STRENGTH-

Q&A for submission of applications for prequalification of Zinc Sulfate tablets and Zinc Sulfate oral liquid (solution)

Withdrawal of Proposed Rule on Supplemental Applications Proposing Labeling Changes for

Brand and Generic Drugs. Educational Objectives. Absorption

Mark M. Yacura. Partner

CHAPTER 1 COMMUNITY PHARMACY M.ASHOKKUMAR DEPT OF PHARMACY PRACTICE SRM COLLEGE OF PHARMACY SRM UNIVERSITY

Compare Results. 153 Replacements 26 Insertions 344 Deletions. Total Changes. Styling and. Content. 0 Annotations. Old File: New File:

SOMNUS VITM Supplement for sleep and wellness

4/26/2013. Libia Lugo Drug Specialist San Juan District Office Investigations Branch

Lamivudine Tablets 150 mg (Macleods Pharmaceuticals Ltd), HA424. WHOPAR Part 5 05/2011, version 1.0 LABELLING. Page 1 of 8

Inspections, Compliance, Enforcement, and Criminal Investigations

RE: Permits under the Arizona Pharmacy Act should not be required for dietary supplements

DEPARTMENT OF HEALTH & HUMAN SERVICES

Getting Your Ingredient to Market: Understanding Your Regulatory Options Venable LLP

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

DESCRIPTION: Each gram of ointment contains 500 units of Bacitracin in a low melting special base containing White Petrolatum and Mineral Oil.

Warnings Allergy alert: Ibuprofen may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include:

7/16/2015. Introduction to USP. The Role of the U.S. Pharmacopeial Convention in Manufacturing OTC Medicines and Dietary Supplements.

InvaGen. FDP..90 fit P(Do47. Citizen petitian

Fang-Chi Chang (M.D.,Ph.D.) Center for Drug Evaluation, Taiwan

Heng-Jung Lien 衛生福利部食品藥物管理署. Section Chief. Food and Drug Administration, Ministry of Health and Welfare

FDA Laws & Pharmacy Practice

John C. Kim, RPh, JD Senior Director, Regulatory Affairs Ferring Pharmaceuticals Inc. 4 Gatehall Drive 3 rd Floor Parsippany, NJ 07054

Prednisolone Sodium Phosphate Ophthalmic Solution USP, 1% (Sterile) Rx only

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry

SUMMARY: The Food and Drug Administration (FDA) is requesting public input on updated

Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry


SNuVASivE: 51. 0(k) Premarket Notification Long Lateral Spinal System

International Pharmaceutical Aerosol Consortium on Regulation and Science

LACHMAN CONSULTANT SERVICES, INC STEWART AVENUE, WESTBURY, NY (516) " FAX (516) $,7,1 OVERNIGHT COURIER 11/16/09

Inspections, Compliance, Enforcement, and Criminal Investigations

Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for. Over-the-Counter Human Use; Amendment of Monograph for OTC Nasal

Do not open the test booklet prior to being told to do so.

LOREAL USA. February 6, Theresa Michelle, M.D.

Understanding Regulatory Global Requirements for Nasal Drug Products. Julie D. Suman, Ph.D. April 8, 2016

MOVICOL Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan-

Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry

FDA Laws & Pharmacy Practice

Guideline on the Regulation of Therapeutic Products in New Zealand

Transcription:

43203-852-47 ANTICOAGULANT CITRATE DEXTROSE A ACD-A National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or processed by it for commercial distribution. (See Section 510 of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. 360)). Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. FDA publishes the listed NDC numbers and the information submitted as part of the listing information in the NDC Directory which is updated daily. 2018

43203-852-47 Anticoagulant Citrate Dextrose A Acd-a Labeler Arteriocyte Medical Systems, Inc. of Company corresponding to the labeler code segment of the ProductNDC. NDC Package Code 43203-852-47 The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC. Proprietary Anticoagulant Citrate Dextrose A Acd-a Also known as the trade name. It is the name of the product chosen by the labeler. 11 Digit NDC Code 43203-0852-47 It should be noted that many NDCs are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a 5-4-2 format. Converting NDCs from a 10-digit to 11-digit format requires a strategically placed zero, dependent upon the 10-digit format. Product NDC 43203-852 The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. Product Type Non Proprietary Package Description Marketing Category Application Number HUMAN PRESCRIPTION DRUG Anticoagulant Citrate Dextrose A Acd-a 50 ml in 1 BAG (43203-852-47) ANDA BA110057 Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the Document Type of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Sometimes called the generic name, this is usually the active ingredient(s) of the product. A description of the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. For example: 4 BOTTLES in 1 CARTON/100 TABLETS in 1 BOTTLE. Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. part 341 ). For unapproved drugs, this field will be null. - 2 -

Product Marketing Start Date 20110511 This is the date that the labeler indicates was the start of its marketing of the drug product. Dosage Form INJECTION, SOLUTION The translation of the DosageForm Code submitted by the firm. The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. Route EXTRACORPOREAL The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Substance CITRIC ACID MONOHYDRATE; SODIUM CITRATE; DEXTROSE MONOHYDRATE This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. Strength Number.08;.22;.245 These are the strength values (to be used with units below) of each active ingredient, listed in the same order as the Substance field above. Strength Unit g/10ml; g/10ml; g/10ml These are the units to be used with the strength values above, listed in the same order as the Substance and SubstanceNumber. Pharmaceutical Classes Acidifying Activity [MoA],Calculi Dissolution Agent [EPC],Anticoagulant [EPC],Decreased Coagulation Factor Activity [PE],Calcium Chelating Activity [MoA],Osmotic Laxative [EPC],Increased Large Intestinal Motility [PE],Inhibition Large Intestine Fluid/Electrolyte Absorption [PE],Osmotic Activity [MoA] These are the reported pharmaceutical class categories corresponding to the Substances listed above. - 3 -

Status Active NDC Code Status: <ul> <li><strong>active</strong> <br/>active NDC Code</li> <li><strong>deprecated</strong> <br/>deprecated NDC Code</li> <li> <strong>unfinished</strong> (Unapproved) <br/>the following status describes submitted unfinished drugs, including the marketing categories of Active Pharmaceutical Ingredient (API), Drug for Further Processing, Bulk for Human Drug Compounding, and Bulk for Animal Drug Compounding. <br/> <strong> FDA does not review and approve unfinished products. Therefore, all products having "unfinished" status are considered unapproved. </strong> </li> </ul> Last Update Date 2015-11-18 The date that a record was last updated or changed. - 4 -

Food and Drug Administration Center for Drug Evaluation and Research Office of Compliance, Immediate Office Drug Registration and Listing Team 10903 New Hampshire Ave Silver Spring, MD 20993-0002 Email: edrls@fda.hhs.gov - 5 -

For all questions regarding this bundle please contact Support@HIPAASpace.com. Also feel free to let us know about any suggestions or concerns. All additional information as well as customer support is available at http://. - 6 -